$547.96
3.97% yesterday
Nasdaq, Jul 15, 10:06 pm CET
ISIN
US75886F1075
Symbol
REGN
Sector
Industry

Regeneron Pharmaceuticals Stock price

$547.96
+25.28 4.84% 1M
-155.47 22.10% 6M
-164.37 23.08% YTD
-534.15 49.36% 1Y
-59.58 9.81% 3Y
-84.78 13.40% 5Y
+4.58 0.84% 10Y
+538.45 5,661.93% 20Y
Nasdaq, Closing price Tue, Jul 15 2025
-22.63 3.97%
ISIN
US75886F1075
Symbol
REGN
Sector
Industry

Key metrics

Basic
Market capitalization
$61.6b
Enterprise Value
$56.0b
Net debt
positive
Cash
$8.3b
Shares outstanding
108.2m
Valuation (TTM | estimate)
P/E
14.1 | 15.8
P/S
4.4 | 4.5
EV/Sales
4.0 | 4.1
EV/FCF
18.9
P/B
2.1
Financial Health
Equity Ratio
77.7%
Return on Equity
15.0%
ROCE
12.0%
ROIC
13.2%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$14.1b | $13.6b
EBITDA
$4.6b | $4.4b
EBIT
$4.1b | $4.0b
Net Income
$4.5b | $3.9b
Free Cash Flow
$3.0b
Growth (TTM | estimate)
Revenue
7.5% | -3.9%
EBITDA
0.7% | -5.5%
EBIT
-0.7% | -5.8%
Net Income
16.6% | -11.5%
Free Cash Flow
-24.6%
Margin (TTM | estimate)
Gross
86.7%
EBITDA
32.4% | 32.5%
EBIT
28.9%
Net
31.9% | 28.6%
Free Cash Flow
21.0%
More
EPS
$40.5
FCF per Share
$27.4
Short interest
2.0%
Employees
15k
Rev per Employee
$940.0k
Show more

Create a Free Account to create an Regeneron Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Regeneron Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a Regeneron Pharmaceuticals forecast:

24x Buy
71%
9x Hold
26%
1x Sell
3%

Analyst Opinions

34 Analysts have issued a Regeneron Pharmaceuticals forecast:

Buy
71%
Hold
26%
Sell
3%

Financial data from Regeneron Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
14,086 14,086
8% 8%
100%
- Direct Costs 1,875 1,875
11% 11%
13%
12,211 12,211
7% 7%
87%
- Selling and Administrative Expenses 3,053 3,053
12% 12%
22%
- Research and Development Expense 5,057 5,057
10% 10%
36%
4,559 4,559
1% 1%
32%
- Depreciation and Amortization 496 496
14% 14%
4%
EBIT (Operating Income) EBIT 4,064 4,064
1% 1%
29%
Net Profit 4,499 4,499
17% 17%
32%

In millions USD.

Don't miss a Thing! We will send you all news about Regeneron Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Regeneron Pharmaceuticals Stock News

Positive
Seeking Alpha
5 days ago
Regeneron Pharmaceuticals, Inc.'s stock continues to remain in the accumulation phase even after the setbacks associated primarily with itepekimab and Eylea. At the same time, Dupixent will remain Regeneron's key "cash cow" and its savior, the profit from sales of which will rise sharply in 2027. From its oncology franchise, I highlight Lynozyfic, which received its first FDA approval on July 2...
Neutral
The Motley Fool
10 days ago
Equity markets have been volatile throughout the year. We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.
Positive
WSJ
13 days ago
Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.
More Regeneron Pharmaceuticals News

Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Head office United States
CEO Leonard Schleifer
Employees 15,158
Founded 1988
Website www.regeneron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today